DE69421936T2 - Stabilisiertes prostaglandin e1 - Google Patents

Stabilisiertes prostaglandin e1

Info

Publication number
DE69421936T2
DE69421936T2 DE69421936T DE69421936T DE69421936T2 DE 69421936 T2 DE69421936 T2 DE 69421936T2 DE 69421936 T DE69421936 T DE 69421936T DE 69421936 T DE69421936 T DE 69421936T DE 69421936 T2 DE69421936 T2 DE 69421936T2
Authority
DE
Germany
Prior art keywords
formulation
lactose
pct
pge
tertiary butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69421936T
Other languages
English (en)
Other versions
DE69421936D1 (de
Inventor
Dirk Teagarden
William Petre
Paul Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE69421936D1 publication Critical patent/DE69421936D1/de
Application granted granted Critical
Publication of DE69421936T2 publication Critical patent/DE69421936T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69421936T 1993-10-27 1994-09-06 Stabilisiertes prostaglandin e1 Expired - Lifetime DE69421936T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14369593A 1993-10-27 1993-10-27
PCT/US1994/009648 WO1995011683A1 (en) 1993-10-27 1994-09-06 Stabilized prostaglandin e¿1?

Publications (2)

Publication Number Publication Date
DE69421936D1 DE69421936D1 (de) 2000-01-05
DE69421936T2 true DE69421936T2 (de) 2000-06-29

Family

ID=22505188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69421936T Expired - Lifetime DE69421936T2 (de) 1993-10-27 1994-09-06 Stabilisiertes prostaglandin e1

Country Status (16)

Country Link
US (2) US5741523A (de)
EP (1) EP0725642B1 (de)
JP (1) JP3999263B2 (de)
KR (1) KR100335549B1 (de)
CN (1) CN1060042C (de)
AT (1) ATE187071T1 (de)
AU (1) AU688792B2 (de)
DE (1) DE69421936T2 (de)
DK (1) DK0725642T3 (de)
ES (1) ES2142409T3 (de)
FI (1) FI116270B (de)
GR (1) GR3032817T3 (de)
NO (1) NO309126B1 (de)
NZ (1) NZ273752A (de)
PT (1) PT725642E (de)
WO (1) WO1995011683A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
KR100195348B1 (ko) * 1996-10-31 1999-06-15 장용택 안정한 프로스타글란딘 e1-함유 주사제 조성물
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
AU742787B2 (en) 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
TR200002543T2 (tr) * 1998-03-03 2000-11-21 Shionogi & Co., Ltd. Fosfolipaz önleyici sodyum [[3-(2-amino-1,2-dioksietil-1-fenilmetil) -2-etil-1-fenilmetil)- 1H-indol-4-il]oksi] asetat içeren farmasötik kompozisyonlar
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6264981B1 (en) † 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
CA2543296A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
CN101933923A (zh) * 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US20100222785A1 (en) * 2007-08-03 2010-09-02 Vanderbilt University Anchor driver
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (de) * 2008-09-25 2015-07-01 Cephalon, Inc. Flüssige Formulierungen aus Bendamustin
SG172810A1 (en) * 2009-01-15 2011-08-29 Cephalon Inc Novel forms of bendamustine free base
ES2875374T3 (es) 2010-01-28 2021-11-10 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
AT518009A1 (de) * 2015-07-27 2017-06-15 Gebro Holding Gmbh Konzentrat enthaltend Alprostadil
CN109394704B (zh) * 2018-11-27 2021-09-17 西安力邦肇新生物科技有限公司 一种前列腺素e1甲酯注射用冻干制剂及制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3952004A (en) * 1974-06-18 1976-04-20 Pfizer Inc. Stabilized E-series prostaglandins
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US5082664A (en) * 1987-05-22 1992-01-21 The Liposome Company, Inc. Prostaglandin-lipid formulations

Also Published As

Publication number Publication date
US5770230A (en) 1998-06-23
NO961718L (no) 1996-04-29
CN1133561A (zh) 1996-10-16
DE69421936D1 (de) 2000-01-05
JPH09504529A (ja) 1997-05-06
JP3999263B2 (ja) 2007-10-31
EP0725642B1 (de) 1999-12-01
US5741523A (en) 1998-04-21
GR3032817T3 (en) 2000-06-30
FI961797A0 (fi) 1996-04-26
ES2142409T3 (es) 2000-04-16
NZ273752A (en) 1998-03-25
CN1060042C (zh) 2001-01-03
AU7716794A (en) 1995-05-22
PT725642E (pt) 2000-05-31
EP0725642A1 (de) 1996-08-14
DK0725642T3 (da) 2000-05-29
NO309126B1 (no) 2000-12-18
FI961797A (fi) 1996-04-26
KR960705572A (ko) 1996-11-08
NO961718D0 (no) 1996-04-29
AU688792B2 (en) 1998-03-19
FI116270B (fi) 2005-10-31
ATE187071T1 (de) 1999-12-15
KR100335549B1 (ko) 2002-11-29
WO1995011683A1 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
ATE187071T1 (de) Stabilisiertes prostaglandin e1
Du Vigneaud et al. The synthesis of oxytocin1
BR9707270A (pt) Processo para o tratamento de tabaco
DE69503604D1 (de) Stabilisierte orthokieselsäure enthaltende zubereitung sowie biologische zubereitung
ATE264689T1 (de) Herstellung von kollagen
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
ES2154676T3 (es) Procedimiento para el aumento de la resistencia de productos celulosicos contra hongos y putrefaccion.
NO301830B1 (no) Krystallinsk laktitol, samt fremgangsmåte ved fremstilling og anvendelse derav
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
ATE413862T1 (de) Stabilisierte natürliche cannabinoid formulierung
Ingham et al. Intestinal absorption of amino acids by rainbow trout, Salmo gairdneri (Richardson)
US5849473A (en) Method of lyophilization of mammalian sperm cells
DE60207039D1 (de) Verfahren zur herstellung von kaffeearomazusammensetzungen
NO951547L (no) Fremgangsmåte for fremstilling av krystaller av veksthormon og krystaller fremstilt ved fremgangsmåten
KR900000544B1 (ko) 저장성 카모밀레 추출물의 제조방법
Jennings et al. Effect of E. coli endotoxin on temperature, oxygen consumption and brown adipose tissue thermogenesis in rats and mice
PT94078A (pt) Processo para a preparacao de derivados de acido butenoico e de composicoes farmaceuticas que os contem
KR910016734A (ko) 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
CA2178396A1 (en) Enhancing keratinocyte migration and proliferation with clostridiopeptidase-a-collagenase
SU959786A1 (ru) Способ консервировани цельной крови
EA200200680A1 (ru) Применение регулятора роста растений на основе семикарбазона для раннего останавливания роста культурных растений
Huang et al. Purification and characterization of collagenase from guinea pig skin
US4226769A (en) Process for preparing a solid preparation of a penicillin derivative
KR900018013A (ko) 시아노아세트아미드 유도체, 그의 제조방법 및 그를 유효 성분으로서 함유하는 식물 병해 방제제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition